Morgan Stanley initiates Immix Biopharma at Overweight with $20 price target

Morgan Stanley initiated coverage on Immix Biopharma with an Overweight rating and a $20 price target. The bank cited NXC-201's 89% complete response rate in relapsed/refractory AL amyloidosis, supporting peak risk-adjusted revenue near $800M.

Detected & updated continuously · Source: Nebula